https://investir.lesechos.fr/conseils-boursiers/conseils-actions/maat-pharma-lapproche-novatrice-du-microbiote-1909546
MaaT PharmaMarch 13, 2023
Hervé Affagard, CEO and co-founder of MaaT Pharma, commented on the first FDA-approval for a…
MaaT PharmaDecember 2, 2022
Hervé Affagard, CEO and co-founder of MaaT Pharma, commented on the first FDA-approval for a…
MaaT PharmaDecember 2, 2022
2022 edition of HealthTech Innovation Days: replay of "Translational microbiome medicine to treat serious oncology…
MaaT PharmaOctober 21, 2022
Interview of Hervé Affagard, CEO and co-founder of MaaT Pharma, for Lyon Décideurs - Bourses…
MaaT PharmaOctober 18, 2022
La Bourse et la Vie interviewed Hervé Affagard, CEO and co-founder of MaaT Pharma, during…
MaaT PharmaOctober 13, 2022
